PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: A01N 37/18, A61K 38/00, C07K 1/00, 2/00, 4/00, 7/00, 14/00, 16/00, 17/00, C07H 21/02, 21/04

A1

(11) International Publication Number: WO 97/48275

(43) International Publication Date: 24 December 1997 (24.12.97)

(21) International Application Number: PCT/US97/10942

(22) International Filing Date: 19 June 1997 (19.06.97)

(30) Priority Data:
60/020,150 20 June 1996 (20.06.96) US
08/878,474 18 June 1997 (18.06.97) US

(71) Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 22nd floor, 300 Lakeside Drive, Oakland, CA 94612 (US).

(72) Inventors: DE ROBERTIS, Edward, M.; 16958 Dulce Ynez Lane, Pacific Palisades, CA 90272 (US). BOUWMEESTER, Tewis; Apartment 708, 827 Levering Avenue, Los Angeles, CA 90024 (US).

(74) Agents: SIEBERT, J., Suzanne et al.; Majestic, Parsons, Siebert & Hsue, Suite 1100, Four Embarcadero Center, San Francisco, CA 94111 (US).

(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
With international search report.

(54) Title: ENDODERM, CARDIAC AND NEURAL INDUCING FACTORS

(57) Abstract

Novel proteins have been designated "cerberus" and "frzb-1", respectively. Cerebus is expressed as a secreted peptide during embryogenesis of the Xenopus embryo, and is expressed specifically in the head organizer region. This new molecule has endodermal, cardiac, and neural tissue inducing activity, that should prove useful in therapeutic, diagnostic, and clinical applications requiring regeneration, differentiation, or repair of these and other tissues. Frzb-1 is a soluble antagonist of growth factors of the Wnt family that acts by binding to Wnt growth factors in the extracellular space. A third novel protein is termed PAPC which promotes the formation of dorsal mesoderm and somites in the embryo.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

ENDODERM, CARDIAC AND NEURAL INDUCING FACTORS

Field of the Invention

The invention generally relates to growth factors, neurotrophic factors, and their inhibitors, and more particularly to several new growth factors with neural, endodermal, and cardiac tissue inducing activity, to complexes and compositions including the factors, and to DNA or RNA coding sequences for the factors. Further, one of the novel growth factors should be useful in tumor suppression gene therapy.

This application claims the benefit of U.S. Provisional Application No. 60/020,150, filed June 20, 1996.

This invention was made with Government support under grant contract number HD-21502, awarded by the National Institutes of Health. The Government has certain rights in this invention.

Background of the Invention

Growth factors are substances, such as polypeptide hormones, which affect the growth of defined populations of animal cells *in vivo* or *in vitro*, but which are not nutrient substances. Proteins involved in the growth and differentiation of tissues may promote or inhibit growth, and promote or inhibit differentiation, and thus the general term "growth factor" includes cytokines, trophic factors, and their inhibitors.

Widespread neuronal cell death accompanies normal development of the central and peripheral nervous systems. Studies of peripheral target tissues during development have shown that neuronal cell death results from the competition among neurons for limiting amounts of survivor factors ("neurotrophic factors"). The earliest identified of these, nerve growth factor ("NGF"), is the most fully characterized and has been shown to be essential for the survival of sympathetic and neural crest-derived sensory neurons during early development of both chick and rat.

One family of neurotropic factors are the Wnts, which have dorsal axis-inducing activity. Most of the Wnt proteins are bound to cell surfaces. (See, e.g., Sokol et al., *Science, 249*, pp. 561-564, 1990.) Dorsal axis-inducing activity in Xenopus embryos by one member of this family (Xwnt-8) was described by Smith and Harland in 1991, *Cell, 67*, pp. 753-765. The authors described using RNA injections as a strategy for identifying endogenous RNAs involved in dorsal patterning to rescue dorsal development in embryos that were ventralized by UV irradiation.

Another member of the growth and neurotropic factor family was subsequently discovered and described by Harland and Smith, which they termed "noggin." (*Cell, 70*, pp. 829-840 (1992).) Noggin is a good candidate to function as a signaling molecule in Nieuwkoop's center, by virtue of its maternal transcripts, and in Spemann's organizer, through its zygotic organizer-specific expression. Besides noggin, other secreted factors may be involved in the organizer phenomenon.

Another Xenopus gene designated "chordin" that begins to be expressed in Spemann's organizer and that can completely rescue axial development in ventralized

embryos was described by Sasai et al., *Cell*, *79*, pp. 779-790, 1994. In addition to dorsalizing mesoderm, chordin has the ability to induce neural tissue and its activities are antagonized by Bone Morphogenetic Protein-4 (Sasai et al., *Nature*, *376*, pp. 333-336, 1995).

Therefore, the dorsal lip or Spemann's organizer of the Xenopus embryo is an ideal tissue for seeking novel growth and neurotrophic factors. New growth and neurotrophic factors are useful agents, particularly those that are secreted due to their ability to be used in physiologically active, soluble forms because these factors, their receptors, and DNA or RNA coding sequences therefore and fragments thereof are useful in a number of therapeutic, clinical, research, diagnostic, and drug design applications.

Summary of the Invention

In one aspect of the present invention, the sequence of the novel peptide that can be in substantially purified form is shown by SEQ ID NO:1. The Xenopus derived SEQ ID NO:1 has been designated "cerberus," and this peptide is capable of inducing endodermal, cardiac, and neural tissue development in vertebrates when expressed. The nucleotide sequence which, when expressed results in cerberus, is illustrated by SEQ ID NO:2. Since peptides of the invention induce endodermal, cardiac, and neural tissue differentiation in vertebrates, they should be able to be prepared in physiologically active form for a number of therapeutic, clinical, and diagnostic applications.

Cerberus was isolated during a search for molecules expressed specifically in Spemann's organizer containing a secretory signal sequence. In addition to cerberus, two other novel cDNAs were identified.

The Xenopus derived peptide that can be deduced from SEQ ID NO:3 encodes a novel protein we had earlier designated as "frazzled," a secreted protein of 318 amino acids that has dorsalizing activity in Xenopus embryos. We now designate the novel protein as "frzb-1." The gene for frzb-1 is expressed in many adult tissues of many animals, three of the cDNAs (Xenopus, mouse, and human) have been cloned by us. The accession numbers for the Xenopus, mouse, and human frzb-1 cDNA sequences of the gene now designated frzb-1 are U68059, U68058, and U68057, respectively. Frzb-1 has some degree of sequence similarity to the Drosophila gene frizzled which has been shown to encode a seven-transmembrane protein that can act both as a signalling and as a receptor protein (Vinson et al., *Nature, 338*, pp. 263-264, 1989; Vinson and Adler, *Nature, 329*, pp. 549-551, 1987). Vertebrate homologues of Frizzled have been isolated and they too were found to be anchored to the cell membrane by seven membrane spanning domains (Wang et al., *J. Biol. Chem., 271*, pp. 4468-4476, 1996). Frzb-1 differs from the frizzled proteins in that it is an entirely soluble, diffusible secreted protein and therefore suitable as a therapeutic agent. The nucleotide sequence derived from Xenopus that, when expressed, results in frzb-1 protein is illustrated by SEQ ID NO:4. The frzb-1 protein derived from mouse is shown as SEQ ID NO:7, while the mouse frzb-1 nucleotide sequence is SEQ ID NO:8. The human derived frzb-1 protein is illustrated by SEQ ID NO:9, and the human frzb-1 nucleotide sequence is SEQ ID NO:10.

Frzb-1 is an antagonist of Wnts *in vivo*, and thus is believed to find utility as a tumor suppressor gene, since overexpressed Wnt proteins cause cancer. Frzb-1 may also be a useful vehicle for solubilization

and therapeutic delivery of Wnt proteins complexed with it.

The final cDNA isolated containing a signal sequence results in a peptide designated Paraxial Protocadherin (PAPC). The cDNA for PAPC is a divergent member of the cadherin multigene family. PAPC is most related to protocadherin 43 reported by Sano et al., *The EMBO J.*, *12*, pp. 2249-2256, 1993. As shown in SEQ ID NO:5, the PAPC gene encodes a transmembrane protein of 896 amino acids, of which 187 are part of an intracellular domain. PAPC is a cell adhesion molecule, and microinjection of PAPC mRNA constructs into Xenopus embryos suggest that PAPC acts as a molecule involved in mesoderm differentiation. A soluble form of the PAPC extracellular domain is able to block muscle and mesoderm formation in Xenopus embryos. The nucleotide sequence encoding Xenopus PAPC is provided in SEQ ID NO:6.

Cerberus, frzb-1, or PAPC or fragments thereof (which also may be synthesized by *in vitro* methods) may be fused (by recombinant expression or *in vitro* covalent methods) to an immunogenic polypeptide and this, in turn, may be used to immunize an animal in order to raise antibodies against the novel proteins. Antibodies are recoverable from the serum of immunized animals. Alternatively, monoclonal antibodies may be prepared from cells from the immunized animal in conventional fashion. Immobilized antibodies are useful particularly in the diagnosis (*in vitro* or *in vivo*) or purification of cerberus, frzb-1, or PAPC.

Substitutional, deletional, or insertional mutants of the novel polypeptides may be prepared by *in vitro* or recombinant methods and screened for immuno-crossreactivity with cerberus, frzb-1, or PAPC and for cerberus antagonist or agonist activity.

Cerberus or frzb-1 also may be derivatized *in vitro* in order to prepare immobilized and labelled proteins, particularly for purposes of diagnosis of insufficiencies thereof, or for affinity purification of antibodies thereto.

Among applications for the novel proteins are tissue replacement therapy and, because frzb-1 is an antagonist of Wnt signaling, tumor suppression therapies. The cerberus receptor may define a novel signalling pathway. In addition, frzb-1 could permit the isolation of novel members of the Wnt family of growth factors.

Brief Description of the Drawings

Figure 1 illustrates the amino acid sequence (SEQ ID NO:1) of the Fig. 2 cDNA clone for cerberus;

Figure 2 illustrates a cDNA clone (SEQ ID NO:2) for cerberus derived from Xenopus. Sense strand is on top (5' to 3' direction) and the antisense strand on the bottom line (in the opposite direction);

Figures 3 and 4 show the amino acid and nucleotide sequence, respectively, of full-length frzb-1 from Xenopus (SEQ ID NOS:3 and 4);

Figures 5 and 6 show the amino acid and nucleotide sequence, respectively, of full-length PAPC from Xenopus (SEQ ID NOS:5 and 6);

Figures 7 and 8 show the amino acid and nucleotide sequence, respectively, of full-length frzb-1 from mouse (SEQ ID NOS:7 and 8); and

Figures 9 and 10 show the amino acid and nucleotide sequence, respectively, of full-length frzb-1 from human (SEQ ID NOS:9 and 10).

Detailed Description of the Preferred Embodiments

Among the several novel proteins and their nucleotide sequences described herein, is a novel endodermal, cardiac, and neural inducing factor in vertebrates that we have named "cerberus." When referring to cerberus, the present invention also contemplates the use of fragments, derivatives, agonists, or antagonists of cerberus molecules. Because cerberus has no homology to any reported growth factors, it is proposed to be the founding member of a novel family of growth factors with potent biological activities, which may be isolated using SEQ ID NO:2.

The amphibian organizer consists of several cell populations with region-specific inducing activities. On the basis of morphogenetic movements, three very different cell populations can be distinguished in the organizer. First, cells with crawling migration movements involute, fanning out to form the prechordal plate. Second, cells involute through the dorsal lip driven by convergence and extension movements, giving rise to the notochord of the trunk. Third, involution ceases and the continuation of mediolateral intercalation movements leads to posterior extension movements and to the formation of the tail notochord and of the chordoneural hinge. The three cell populations correspond to the head, trunk, and tail organizers, respectively.

The cerberus gene is expressed at the right time and place to participate in cell signalling by Spemann's organizer. Specifically, cerberus is expressed in the head organizing region that consists of crawling-migrating cells. The cerberus expressing region corresponds to the prospective foregut, including the liver and pancreas anlage, and the heart mesoderm.

Cerberus expression is activated by chordin, noggin, and organizer-specific homeobox genes.

Our studies were conducted in early embryos of the frog Xenopus laevis. The frog embryo is well suited to experiments, particularly experiments pertaining to generating and maintaining regional differences within the embryo for determining roles in tissue differentiation. It is easy to culture embryos with access to the embryos even at very early stages of development (preceding and during the formation of body pattern and differentiation) and the embryos are large. The initial work with noggin and chordin also had been in Xenopus embryos, and, as predicted, was highly conserved among vertebrates. Predictions based on work with Xenopus as to corresponding human noggin were proven true and the ability to clone the gene for human noggin was readily accomplished. (See the description of Xenopus work and cloning information in PCT application, published March 17, 1994, WO 9 405 800, and the subsequent human cloning based thereon in the PCT application, also published March 17, 1994, as WO 9 405 791.)

CLONING

The cloning of cerberus, frzb-1, and PAPC resulted from a comprehensive screen for cDNAs enriched in Spemann's organizer. Subtractive differential screening was performed as follows. In brief, poly A^+ RNA was isolated from 300 dorsal lip and ventral marginal zone (VMZ) explants at stage 10½. After first strand cDNA synthesis approximately 70-80% of common sequences were removed by substraction with biotinylated VMZ poly A^+ RNA prepared from 1500 ventral gastrula halves. For differential screening, duplicate filters (2000 plaques per 15 cm plate, a total of 80,000 clones

screened) of an unamplified oriented dorsal lip library were hybridized with radiolabeled dorsal lip or VMZ cDNA. Putative organizer-specific clones were isolated, grouped by sequence analysis from the 5' end and whole-mount in situ hybridization, and subsequently classified into known and new dorsal-specific genes. Rescreening of the library (100,000 independent phages) with a cerberus probe resulted in the isolation of 45 additional clones, 31 of which had similar size as the longest one of the 11 original clones indicating that they were presumably full-length cDNAs. The longest cDNAs for cerberus, frzb-1, and PAPC were completely sequenced.

To explore the molecular complexity of Spemann's organizer we performed a comprehensive differential screen for dorsal-specific cDNAs. The method was designed to identify abundant cDNAs without bias as to their function. As shown in Table 1, five previously known cDNAs and five new ones were isolated, of which three (expressed as cerberus, frzb-1, and PAPC, respectively) had secretory signal sequences.

TABLE 1

Previously Known Genes	Gene Product	No. of Isolates
Chordin	novel secreted protein	70
Goosecoid	homeobox gene	3
Pintallavis/XFKH-1	forkhead/transcription factor	2
Xnot-2	homeobox gene	1
Xlim-1	homeobox gene	1
New Genes		
Cerberus	novel secreted protein	11
PAPC	cadherin-like/transmembrane	2
Frzb-1	novel secreted protein	1
Sox-2	sry/transcription factor	1
Fkh-like	forkhead/transcription factor	1

The most abundant dorsal-specific cDNA was chordin (chd), with 70 independent isolates. The second most abundant cDNA was isolated 11 times and named cerberus (after a mythological guardian dog with multiple heads). The cerberus cDNA encodes a putative secreted polypeptide of 270 amino acids, with an amino terminal hydrophobic signal sequence and a carboxy terminal cysteine-rich region (Fig. 1). Cerberus is expressed specifically in the head organizer region of the Xenopus embryo, including the future foregut.

An abundant mRNA found in the dorsal region of the Xenopus gastrula encodes the novel putative secreted protein we have designated as cerberus. Cerberus mRNA has potent inducing activity in Xenopus embryos, leading to the formation of ectopic heads. Unlike other organizer-specific factors, cerberus does not dorsalize mesoderm and is instead an inhibitor of trunk-tail mesoderm. Cerberus is expressed in the anterior-most

domain of the gastrula including the leading edge of the deep layer of the dorsal lip a region that, as shown here, gives rise to foregut and midgut endoderm. Cerberus promotes the formation of cement gland, olfactory placodes, cyclopic eyes, forebrain, and duplicated heart and liver (a foregut derivative). Because the pancreas is also derived from this foregut region, it is likely that cerberus induces pancreas in addition to liver. The expression pattern and inducing activities of cerberus suggest a role for a previously neglected region of the embryo, the prospective foregut endoderm, in the induction of the anterior head region of the embryo.

Turning to Fig. 1, Xenopus cerberus encodes a putative secreted protein transiently expressed during embryogenesis and the deduced amino acid sequence of Xenopus cerberus is shown. The signal peptide sequence and the nine cysteine residues in the carboxy-terminus are indicated in bold. Potential N-linked glycosylation sites are underlined. In database searches the cerberus protein showed limited similarity only to the mammalian Dan protein, a possible tumor suppressor proposed to be a DNA-binding protein.

Cerberus appears to be a pioneer protein, as its amino acid sequence and the spacing of its 9 cysteine residues were not significantly similar to other proteins in the databases (NCBI-Gen Bank release 93.0). We conclude that the second most abundant dorsal-specific cDNA encodes a novel putative secreted factor, which should be the founding member of a novel family of growth factors active in cell differentiation.

<u>Cerberus Demarcates an Anterior Organizer Domain</u>. Cerberus mRNA is expressed at low levels in the unfertilized egg, and zygotic transcripts start accumulating at early gastrula. Expression continues

during gastrula and early neurula, rapidly declining during neurulation. Importantly, cerberus expression starts about one hour after that of chd, suggesting that cerberus could act downstream of the chd signal.

Whole-mount *in situ* hybridizations reveal that expression starts in the yolky endomesodermal cells located in the deep layer of the organizer. The cerberus domain includes the leading edge of the most anterior organizer cells and extends into the lateral mesoderm. The leading edge gives rise to liver, pancreas, and foregut in its midline, and the more lateral region gives rise to heart mesoderm at later stages of development.

Fig. 2 sets out the sequence of a full length Xenopus cDNA for cerberus.

This entirely new molecule has demonstrated physiological properties that should prove useful in therapeutic, diagnostic, and clinical applications that require regeneration, differentiation, or repair of tissues, such wound repair, neuronal regenerational or transplantation, supplementation of heart muscle differentiation, differentiation of pancreas and liver, and other applications in which cell differentiation processes are to be induced.

The second, novel, secreted protein we have discovered is called "frzb-1," which was shown to be a secreted protein in Xenopus oocyte microinjection experiments. Thus it provides a natural soluble form of the related extracellular domains of Drosophila and vertebrate frizzled proteins. We propose that the latter proteins could be converted into active soluble forms by introducing a stop codon before the first transmembrane domain. We have noted that the cysteine-rich region of frzb-1 and frizzled contains some overall structural homology with Wnt proteins using the Profile

Search homology program (Gribskov, *Meth. Enzymol.*, *183*, pp. 146-159, 1990). This had raised the interesting possibility that frzb-1 could interact directly with Wnt growth factors in the extracellular space. This was because we had found that when microinjected into Xenopus embryos, frzb-1 constructs have moderate dorsalizing activity, leading to the formation of embryos with enlarged brain and head, and shortened truck. Somatic muscle differentiation, which requires Xwnt-8, was inhibited. In the case of frzb-1, an attractive hypothesis, suggested by the structural homologies, was that it may act as an inhibitor of Wnt-8, a growth factor that has ventralizing activity in the Xenopus embryo (Christian and Moon, *Genes Dev.*, *7*, pp. 13-28, 1993). We have shown that frzb-1 can interact with Xwnt-8 and Wnt-1, and it is expected that it could also interact with other members of the Wnt family of growth factors, of which at least 15 members exist in mammals. In addition, a possible interaction with Wnts was suggested by the recent discovery that dishevelled, a gene acting downstream of wingless, has strong genetic interaction with frizzled mutants in Drosophila (Krasnow et al., *Development*, *121*, pp. 4095-4102, 1995). This possibility has been explored in depth (Leyns et al., *Cell*, *88*, pp. 747-756, March 21, 1997), because a soluble antagonist of the Wnt family of proteins is expected to be of great therapeutic value. Examples 1 and 2 illustrate tests that show antagonism of Xwnt-8 by binding to frzb-1.

Vertebrate homologues of Frizzled have been isolated and they too are anchored to the cell membrane by seven membrane spanning domains (Wang et al., *J. Biol. Chem.*, *271*, pp. 4468-4476, 1996). Frzb-1 differs from the frizzled proteins in that it is an entirely soluble, diffusible secreted protein and

therefore suitable as a therapeutic agent. The nucleotide sequence that when expressed results in frzb-1 protein is illustrated by SEQ ID NO:4.

SEQ ID NO:4 corresponds to the Xenopus homolog, but by using it in BLAST searches (and by cloning mouse frzb-1) we had been able to assemble the sequence of the entire mature human frzb-1 protein, SEQ ID NO:9. Indeed, human frzb-1 is encoded in six expressed sequence tags (ESTs) available in Genebank. The human frzb-1 sequence can be assembled by overlapping in the 5' to 3' direction the ESTs with the following accession numbers in Genebank: H18848, R63748, W38677, W44760, H38379, and N71244. No function had yet been assigned to these EST sequences, but we believe and thus propose here that human frzb-1 will have similar functions in cell differentiation to those described above for Xenopus frzb-1. The nucleotide sequence of human frzb-1 is shown in SEQ ID NO:10. The mouse frzb-1 protein and nucleotide sequences are provided by SEQ ID NOS:7 and 8, respectively.

In particular, we believe that frzb-1 will prove useful in gene therapy of human cancer cells. In this rapidly developing field, one approach is to introduce vectors expressing anti-sense sequences to block expression of dominant ocogenes and growth factor receptors. Another approach is to produce episomal vectors that will replicate in human cells in a controlled fashion without transforming the cells. For an example of the latter (an episomal expression vector system for human gene therapy), reference is made to U.S. Patent 5,624,820, issued April 29, 1997, inventor Cooper.

Gene therapy now includes uses of human tumor suppression genes. For example, U.S. Patent 5,491,064, issued February 13, 1996, discloses a tumor suppression

gene localized on chromosome 11 and described as potentially useful for gene therapy in cancers deleted or altered in their expression of that gene. Frzb-1 maps to chromosome 2q31-33 and loss of one copy of the 2q31-33 and loss of one copy of the 2q arm has been observed with high incidence in lung carcinomas, colo-rectal carcinomas, and neuroblastomas, which has lead to the proposal that the 2q arm carries a tumor suppressor gene. We expect frzb to be a tumor suppressor gene, and thus to be useful in tumor suppression applications.

A number of applications for cerberus and frzb-1 are suggested from their pharmacological (biological activity) properties.

For example, the cerberus and frzb-1 cDNAs should be useful as a diagnostic tool (such as through use of antibodies in assays for proteins in cell lines or use of oligonucleotides as primers in a PCR test to amplify those with sequence similarities to the oligonucleotide primer, and to determine how much of the novel protein is present).

Cerberus, of course, might act upon its target cells via its own receptor. Cerberus, therefore, provides the key to isolate this receptor. Since many receptors mutate to cellular oncogenes, the cerberus receptor should prove useful as a diagnostic probe for certain tumor types. Thus, when one views cerberus as ligand in complexes, then complexes in accordance with the invention include antibody bound to cerberus, antibody bound to peptides derived from cerberus, cerberus bound to its receptor, or peptides derived from cerberus bound to its receptor or other factors. Mutant forms of cerberus, which are either more potent agonists or antagonists, are believed to be clinically useful.

Such complexes of cerberus and its binding protein partners will find uses in a number of applications.

Practice of this invention includes use of an oligonucleotide construct comprising a sequence coding for cerberus or frzb-1 and for a promoter sequence operatively linked in a mammalian or a viral expression vector. Expression and cloning vectors contain a nucleotide sequence that enables the vector to replicate in one or more selected host cells. Generally, in cloning vectors this sequence is one that enables the vector to replicate independently of the host chromosomes, and includes origins of replication or autonomously replicating sequences. The well-known plasmid pBR322 is suitable for most gram negative bacteria, the 2μ plasmid origin for yeast and various viral origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for cloning vectors in mammalian cells.

Expression and cloning vectors should contain a selection gene, also termed a selectable marker. Typically, this is a gene that encodes a protein necessary for the survival or growth of a host cell transformed with the vector. The presence of this gene ensures that any host cell which deletes the vector will not obtain an advantage in growth or reproduction over transformed hosts. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g. ampicillin, neomycin, methotrexate or tetracycline, (b) complement auxotrophic deficiencies.

Examples of suitable selectable markers for mammalian cells are dihydrofolate reductase (DHFR) or thymidine kinase. Such markers enable the identification of cells which were competent to take up the cerberus nucleic acid. The mammalian cell transformants are placed under selection pressure which only the transformants are uniquely adapted to survive by virtue

of having taken up the marker. Selection pressure is imposed by culturing the transformants under conditions in which the concentration of selection agent in the medium is successively changed. Amplification is the process by which genes in greater demand for the production of a protein critical for growth are reiterated in tandem within the chromosomes of successive generations of recombinant cells. Increased quantities of cerberus or frzb-1 can therefor be synthesized from the amplified DNA.

For example, cells transformed with the DHFR selection gene are first identified by culturing all of the transformants in a culture medium which contains methotrexate (Mtx), a competitive antagonist of DHFR. An appropriate host cell in this case is the Chinese hamster ovary (CHO) cell line deficient in DHFR activity, prepared and propagated as described by Urlaub and Chasin, *Proc. Nat. Acac. Sci.*, 77, 4216 (1980). The transformed cells then are exposed to increased levels of Mtx. This leads to the synthesis of multiple copies of the DHFR gene and, concomitantly, multiple copies of other DNA comprising the expression vectors, such as the DNA encoding cerberus or frzb-1. Alternatively, host cells transformed by an expression vector comprising DNA sequences encoding cerberus or frzb-1 and aminoglycoside 3' phosphotransferase (APH) protein can be selected by cell growth in medium containing an aminoglycosidic antibiotic such as kanamycin or neomycin or G418. Because eukaryotic cells do not normally express an endogenous APH activity, genes encoding APH protein, commonly referred to as neo resistant genes, may be used as dominant selectable markers in a wide range of eukaryotic host cells, by which cells transformed by the vector can readily be identified.

Expression vectors, unlike cloning vectors, should contain a promoter which is recognized by the host organism and is operably linked to the cerberus nucleic acid. Promoters are untranslated sequences located upstream from the start codon of a structural gene (generally within about 100 to 1000 bp) that control the transcription and translation of nucleic acid under their control. They typically fall into two classes, inducible and constitutive. Inducible promoters are promoters that initiate increased levels of transcription from DNA under their control in response to some change in culture conditions, e.g. the presence or absence of a nutrient or a change in temperature. At this time a large number of promoters recognized by a variety of potential host cells are well known. These promoters can be operably linked to cerberus encoding DNA by removing them from their gene of origin by restriction enzyme digestion, followed by insertion 5' to the start codon for cerberus or frzb-1.

Nucleic acid is operably linked when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein which participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, operably linked means that the DNA sequences being linked are contiguous and, in the case of a secretory leader, contiguous and in reading phase. Linking is accomplished by ligation at convenient restriction sites. If such sites do not

exit then synthetic oligonucleotide adapters or linkers are used in accord with conventional practice.

Transcription of the protein-encoding DNA in mammalian host cells is controlled by promoters obtained from the genomes of viruses such as polyoma, cytomegalovirus, adenovirus, retroviruses, hepatitis-B virus, and most preferably Simian Virus 40 (SV40), or from heterologous mammalian promoters, e.g. the actin promoter. Of course, promoters from the host cell or related species also are useful herein.

Cerberus and frzb-1 are clearly useful as a component of culture media for use in culturing cells, such as endodermal, cardiac, and nerve cells, *in vitro*. We believe cerberus and frzb-1 will find uses as agents for enhancing the survival or inducing the growth of liver, pancreas, heart, and nerve cells, such as in tissue replacement therapy.

The final cDNA isolated containing a signal sequence results in a peptide designated Paraxial Protocadherin (PAPC). The cDNA for PAPC is a divergent member of the cadherin multigene family. PAPC is most related to protocadherin 43 reported by Sano et al., *The EMBO J.*, *12*, pp. 2249-2256, 1993. As shown in SEQ ID NO:5, the PAPC gene encodes a transmembrane protein of 896 amino acids, of which 187 are part of an intracellular domain. PAPC is a cell adhesion molecule, and microinjection of PAPC mRNA constructs into Xenopus embryos suggest that PAPC acts in mesoderm differentiation. The nucleotide sequence encoding Xenopus PAPC is provided in SEQ ID NO:6.

Therapeutic formulations of the novel proteins may be prepared for storage by mixing the polypeptides having the desired degree of purity with optional physiologically acceptable carriers, excipients or stabilizers, in the form of lyophilized cake or aqueous

solutions. Acceptable carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin or immunoglobulins. Other components can include glycine, blutamine, asparagine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as Tween, Pluronics or PEG.

Polyclonal antibodies to the novel proteins generally are raised in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections of cerberus or frzb-1 and an adjuvant. It may be useful to conjugate these proteins or a fragment containing the target amino acid sequence to a protein which is immunogenic in the species to be immunized, e.g., keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivatizing agent, for example, maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues), N-hydroxysuccinimide (through lysine residues), glutaraldehyde, succinic anhydride, $SOCl_2$, or $R^1N = C = NR$.

Animals can be immunized against the immunogenic conjugates or derivatives by combining 1 mg or 1 μg of conjugate (for rabbits or mice, respectively) with 3 volumes of Freund's complete adjuvant and injecting the solution intradermally in multiple sites. One month later the animals are boosted with 1/5 to 1/10 the original amount of conjugate in Fruend's complete

adjuvant by subcutaneous injection at multiple sites. Seven to 14 days later animals are bled and the serum is assayed for anti-cerberus titer. Animals are boosted until the titer plateaus. Preferably, the animal is boosted with the conjugate of the same cerberus or frzb-1 polypeptide, but conjugated to a different protein and/or through a different cross-linking agent. Conjugates also can be made in recombinant cell culture as protein fusions. Also, aggregating agents such as alum are used to enhance the immune response.

Monoclonal antibodies are prepared by recovering spleen cells from immunized animals and immortalizing the cells in conventional fashion, e.g. by fusion with myeloma cells or by EB virus transformation and screening for clones expressing the desired antibody.

Antibodies are useful in diagnostic assays for cerberus, frzb-1, or PAPC or their antibodies and to identify family members. In one embodiment of a receptor binding assay, an antibody composition which binds to all of a selected plurality of members of the cerberus family is immobilized on an insoluble matrix, the test sample is contacted with the immobilized antibody composition in order to adsorb all cerberus family members, and then the immobilized family members are contacted with a plurality of antibodies specific for each member, each of the antibodies being individually identifiable as specific for a predetermined family member, as by unique labels such as discrete fluorophores or the like. By determining the presence and/or amount of each unique label, the relative proportion and amount of each family member can be determined.

The antibodies also are useful for the affinity purification of the novel proteins from

recombinant cell culture or natural sources. Antibodies that do not detectably cross-react with other growth factors can be used to purify the proteins free from these other family members.

EXAMPLE 1

Frzb-1 Antagonizes Xwnt-8 Non-Cell Autonomously

To test whether frzb-1 can antagonize secondary axes caused by Xwnt-8 after secretion by injected cells, an experimental design was used. Thus, frzb-1 mRNA was injected into each of the four animal blastomeres of eight-cell embryos, and subsequently, a single injection of Xwnt-8 mRNA was given to a vegetal-ventral blastomere at the 16-32 cell stage. In two independent experiments, we found that injection of frzb-1 alone (n=13) caused mild dorsalization with enlargement of the cement gland in all embryos and that injection of Xwnt-8 alone (n=53) lead to induction of complete secondary axes in 67% of the embryos. However, injection of frzb-1 into animal caps abolished the formation of complete axes induced by Xwnt-8 (n=27), leaving only a residual 14% of embryos with very weak secondary axes. The double-injected embryos retained the enlarged cement gland phenotype caused by injection of frzb-1 mRNA alone. Because both mRNAs encode secreted proteins and were microinjected into different cells, we conclude that the antagonistic effects of frzb-1 and Xwnt-8 took place in the extracellular space after these proteins were secreted.

EXAMPLE 2

Membrane-Anchored Wnt-1 Confers Frzb-1 Binding

To investigate a possible interaction between frzb-1 and Wnts, the first step was to insert an HA epitope tag into a Xenopus frzb-1 construct driven by the CMV (cytomegalovirus) promoter. Frzb1-HA was tested in mRNA microinjection assays in Xenopus embryos and found to be biologically active. Conditioned medium from transiently transfected cells contained up to 10 μg/ml of Frzb1-HA (quantitated on Western blots using an HA-tagged protein standard).

Transient transfection of 293 cells has been instrumental in demonstrating interactions between wingless and frizzled proteins. We therefore took advantage of constructs in which Wnt-1 was fused at the amino terminus of CD8, generating a transmembrane protein containing biologically active Wnt-1 exposed to the extracellular compartment. A Wnt1CD8 cDNA construct (a generous gift of Dr. H. Varmus, NIH) was subcloned into the pcDNA (Invitrogen) vector and transfected into 293 cells. After incubation with Frzb1-HA-conditioned medium (overnight at 37°C), intensely labeled cells were observed by immunofluorescence. As a negative control, a construct containing 120 amino acids of Xenopus chordin, an unrelated secreted protein was used. Transfection of this construct produced background binding of Frzb1-HA to the extracellular matrix, both uniform and punctate. Cotransfection of Wnt1CD8 with pcDNA-LacZ showed that transfected cells stained positively for Frzb1-HA and LacZ. Since Wnt1CD8 contains the entire CD8 molecule, a CD8 cDNA was used as an additional negative control. After transfection with LacZ and full-length CB8, Frzb1-HA failed to bind to the transfected cells. Although most of our experiments

were carried out at 37°C, Frzb1-HA-conditioned medium also stained Wnt1CD8-transfected cells after incubation at 4°C for 2 hours.

Attempts to biochemically quantitate the binding of Frzb-1 to Wnt1CD8-transfected cells were unsuccessful due to high background binding to control cultures, presumably due to binding to the extracellular matrix. Thus, we were unable to estimate a K_D for the affinity of the Frzb-1/Wnt-1 interaction. However, when serial dilutions of conditioned medium containing Frzb1-HA were performed (ranging from 2.5×10^{-7} to 1.25×10^{-10} M), staining of Wnt1CD8-transfected cells was found at all concentrations.

Although we have been unable to provide biochemical evidence for direct binding between Wnts and frzb-1, this cell biological assay indicates that Frzb1-HA can bind, directly or indirectly, to Wnt-1 on the cell membrane in the 10^{-10} M range.

It is to be understood that while the invention has been described above in conjunction with preferred specific embodiments, the description and examples are intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims.

It is Claimed:

1. A substantially pure protein characterized by a physiologically active form and comprising an amino acid sequence encoded by the DNA of SEQ ID NO:2.

2. The protein as in claim 1 having neurotrophic, growth or differentiation factor activity.

3. A composition comprising the protein of claim 1 and a physiologically acceptable carrier with which the peptide is admixed.

4. An oligonucleotide construct comprising a sequence coding for a protein and an expression vector operatively linked therewith, the protein having neurotrophic, growth or differentiation factor activity and being expressible from SEQ ID NO:2.

5. The construct as in claim 4 wherein the expression vector is a mammalian or viral expression vector.

6. A substantially pure protein characterized by a physiologically active form and comprising an amino acid sequence encoded by the DNA of SEQ ID NO:4, SEQ ID NO:8, or SEQ ID NO:10.

7. The protein as in claim 6 having neurotrophic, growth or differentiation factor activity.

8. A composition comprising the protein of claim 6 and a physiologically acceptable carrier with which the protein is admixed.

9. An oligonucleotide construct comprising a sequence coding for a protein and an expression vector operatively linked therewith, the protein being expressible from SEQ ID NO:4, SEQ ID NO:8 or SEQ ID NO:10.

10. The construct as in claim 9 wherein the protein is expressible in soluble form.

11. The construct as in claim 9 wherein the expression vector is a mammalian or viral expression vector.

12. A complex comprising a substantially pure frzb-1 protein complexed with at least one Wnt protein.

13. A substantially pure protein characterized by a physiologically active form and comprising an amino acid sequence encoded by the DNA of SEQ ID NO:6.

14. The protein as in claim 13 having mesoderm differentiation activity.

15. A composition comprising the protein of claim 13 and a physiologically acceptable carrier with which the protein is admixed.

MLLNVLRICI	IVCLVNDGAG	KHSEGRERTK	TYSLNSRGYF	40
RKERGARRSK	ILLVNTKGLD	EPHIGEGDFG	LVAELFDSTR	80
THTNRKEPDM	NKVKLFSTVA	EGNKSARRKA	YNGSRRNIPS	120
RRSFDKRNTE	VTEKPGAKMF	WNNFLVKMNG	APQNTSEGSK	160
AQEIMKEACK	TLPFTQNIVH	ENCDRMVIQN	NLCFGKCISL	200
HVPNQQDRRN	TCSHCLPSKF	TLNHLTLNCT	GSKNVVKVVM	240
MVEECTCEAH	KSNFHQTAQF	NMDTSTTLHH		270

Figure 1

```
GAATTCCCAG CAAGTCGCTC AGAAACACTG CAGGGTCTAG ATATCATACA ATGTTACTAA      60
CTTAAGGGTC GTTCAGCGAG TCTTTGTGAC GTCCCAGATC TATAGTATGT TACAATGATT

ATGTACTCAG GATCTGTATT ATCGTCTGCC TTGTGAATGA TGGAGCAGGA AAACACTCAG     120
TACATGAGTC CTAGACATAA TAGCAGACGG AACACTTACT ACCTCGTCCT TTTGTGAGTC

AAGGACGAGA AAGGACAAAA ACATATTCAC TTAACAGCAG AGGTTACTTC AGAAAAGAAA     180
TTCCTGCTCT TTCCTGTTTT TGTATAAGTG AATTGTCGTC TCCAATGAAG TCTTTTCTTT

GAGGAGCACG TAGGAGCAAG ATTCTGCTGG TGAATACTAA AGGTCTTGAT GAACCCCACA     240
CTCCTCGTGC ATCCTCGTTC TAAGACGACC ACTTATGATT TCCAGAACTA CTTGGGGTGT

TTGGGCATGG TGATTTTCGC TTAGTAGCTG AACTATTTGA TTCCACCAGA ACACATACAA     300
AACCCGTACC ACTAAAAGCG AATCATCGAC TTGATAAACT AAGGTGGTCT TGTGTATGTT

ACAGAAAAGA GCCAGACATG AACAAAGTCA AGCTTTTCTC AACAGTTGCC CATGGAAACA     360
TGTCTTTTCT CGGTCTGTAC TTGTTTCAGT TCGAAAAGAG TTGTCAACGG GTACCTTTGT

AAAGTGCAAG AAGAAAAGCT TACAATGGTT CTAGAAGGAA TATTTTTCCT CGCCGTTCTT     420
TTTCACGTTC TTCTTTTCGA ATGTTACCAA GATCTTCCTT ATAAAAAGGA GCGGCAAGAA

TTGATAAAAG AAATACAGAG GTTACTGAAA AGCCTGGTGC CAAGATGTTC TGGAACAATT     480
AACTATTTTC TTTATGTCTC CAATGACTTT TCGGACCACG GTTCTACAAG ACCTTGTTAA

TTTTGGTTAA AATGAATGGA GCCCCACAGA ATACAAGCCA TGGCAGTAAA GCACAGGAAA     540
AAAACCAATT TTACTTACCT CGGGGTGTCT TATGTTCGGT ACCGTCATTT CGTGTCCTTT

TAATGAAAGA AGCTTGCAAA ACCTTGTTTT TCACTCAGAA TATTGTACAT GAAAACTGTG     600
ATTACTTTCT TCGAACGTTT TGGAACAAAA AGTGAGTCTT ATAACATGTA CTTTTGACAC

ACAGGATGGT GATACAGAAC AATCTGTGCT TTGGTAAATG CATCTCTCTC CATGTTCCAA     660
TGTCCTACCA CTATGTCTTG TTAGACACGA AACCATTTAC GTAGAGAGAG GTACAAGGTT

ATCAGCAAGA TCGACGAAAT ACTTGTTCCC ATTGCTTGCC GTCCAAATTT ACCCTGAACC     720
TAGTCGTTCT AGCTGCTTTA TGAACAAGGG TAACGAACGG CAGGTTTAAA TGGGACTTGG

ACCTGACGCT GAATTGTACT GGATCTAAGA ATGTAGTAAA GGTTGTCATG ATGGTAGAGG     780
TGGACTGCGA CTTAACATGA CCTAGATTCT TACATCATTT CCAACAGTAC TACCATCTCC

AATGCACGTG TGAAGCTCAT AAGAGCAACT TCCACCAAAC TGCACAGTTT AACATGGATA     840
TTACGTGCAC ACTTCGAGTA TTCTCGTTGA AGGTGGTTTG ACGTGTCAAA TTGTACCTAT

CATCTACTAC CCTGCACCAT TAAAGGACTG CCATACAGTA TGGAAATGCC CTTTTGTTGG     900
GTAGATGATG GGACGTGGTA ATTTCCTGAC GGTATGTCAT ACCTTTACGG GAAAACAACC

AATATTTGTT ACATACTATG CATCTAAAGC ATTATGTTGC CTTCTATTTC ATATAACCAC     960
TTATAAACAA TGTATGATAC GTAGATTTCG TAATACAACG GAAGATAAAG TATATTGGTG

ATGGAATAAG GATTGTATGA ATTATAATTA ACAAATGGCA TTTTGTGTAA CATGCAAGAT    1020
TACCTTATTC CTAACATACT TAATATTAAT TGTTTACCGT AAAACACATT GTACGTTCTA
```

Figure 2A

```
CTCTGTTCCA TCAGTTGCAA GATAAAAGGC AATATTTGTT TGACTTTTTT TCTACAAAAT   1080
GAGACAAGGT AGTCAACGTT CTATTTTCCG TTATAAACAA ACTGAAAAAA AGATGTTTTA

GAATACCCAA ATATATGATA AGATAATGGG GTCAAAACTG TTAAGGGGTA ATGTAATAAT   1140
CTTATGGGTT TATATACTAT TCTATTACCC CAGTTTTGAC AATTCCCCAT TACATTATTA

AGGGACTAAG TTTGCCCAGG AGCAGTGACC CATAACAACC AATCAGCAGG TATGATTTAC   1200
TCCCTGATTC AAACGGGTCC TCGTCACTGG GTATTGTTGG TTAGTCGTCC ATACTAAATG

TGGTCACCTG TTTAAAAGCA AACATCTTAT TGGTTGCTAT GGGTTACTGC TTCTGGGCAA   1260
ACCAGTGGAC AAATTTTCGT TTGTAGAATA ACCAACGATA CCCAATGACG AAGACCCGTT

AATGTGTGCC TCATAGGGGG GTTAGTGTGT TGTGTACTGA ATAAATTGTA TTTATTTCAT   1320
TTACACACGG AGTATCCCCC CAATCACACA ACACATGACT TATTTAACAT AAATAAAGTA

TGTTACAAAA AAAAAAAA
ACAATGTTTT TTTTTTTT
```

Figure 2B

MSRTRKVDSL LLLAIPGLAL LLLPNAYCAS CEPVRIPMCK SMPWNMTKMP NHLHHSTQAN 60
AILAIEQFEG LLTTECSQDL LFFLCAMYAP ICTIDFQHEP IKPCKSVCER ARAGCEPILI 120
KYRHTWPESL ACEELPVYDR GVCISPEAIV TVEQGTDSMP DFSMDSNNGN CGSGREHCKC 180
KPMKATQKTY LKNNYNYVIR AKVKEVKVKC HDATAIVEVK EILKSSLVNI PKDTVTLYTN 240
SGCLCPQLVA NEEYIIMGYE DKERTRLLLV EGSLAEKWRD RLAKKVKRWD QKLRRPRKSK 300
DPVAPIPNKN SNSRQARS

Figure 3

```
GAATTCCCTT TCACACAGGA CTCCTGGCAG AGGTGAATGG TTAGCCCTAT GGATTTGGTT      60
CTTAAGGGAA AGTGTGTCCT GAGGACCGTC TCCACTTACC AATCGGGATA CCTAAACCAA

TGTTGATTTT GACACATGAT TGATTGCTTT CAGATAGGAT TGAAGGACTT GGATTTTTAT     120
ACAACTAAAA CTGTGTACTA ACTAACGAAA GTCTATCCTA ACTTCCTGAA CCTAAAAATA

CTAATTCTGC ACTTTTAAAT TATCTGAGTA ATTGTTCATT TTGTATTGGA TGGGACTAAA     180
GATTAAGACG TGAAAATTTA ATAGACTCAT TAACAAGTAA AACATAACCT ACCCTGATTT

GATAAACTTA ACTCCTTGCT TTTGACTTGC CCATAAACTA TAAGGTGGGG TGAGTTGTAG     240
CTATTTGAAT TGAGGAACGA AAACTGAACG GGTATTTGAT ATTCCACCCC ACTCAACATC

TTGCTTTTAC ATGTGCCCAG ATTTTCCCTG TATTCCCTGT ATTCCCTCTA AAGTAAGCCT     300
AACGAAAATG TACACGGGTC TAAAAGGGAC ATAAGGGACA TAAGGGAGAT TTCATTCGGA

ACACATACAG GTTGGGCAGA ATAACAATGT CTCGAACAAG GAAAGTGGAC TCATTACTGC     360
TGTGTATGTC CAACCCGTCT TATTGTTACA GAGCTTGTTC CTTTCACCTG AGTAATGACG

TACTGGCCAT ACCTGGACTG GCGCTTCTCT TATTACCCAA TGCTTACTGT GCTTCGTGTG     420
ATGACCGGTA TGGACCTGAC CGCGAAGAGA ATAATGGGTT ACGAATGACA CGAAGCACAC

AGCCTGTGCG GATCCCCATG TGCAAATCTA TGCCATGGAA CATGACCAAG ATGCCCAACC     480
TCGGACACGC CTAGGGGTAC ACGTTTAGAT ACGGTACCTT GTACTGGTTC TACGGGTTGG

ATCTCCACCA CAGCACTCAA GCCAATGCCA TCCTGGCAAT TGAACAGTTT GAAGGTTTGC     540
TAGAGGTGGT GTCGTGAGTT CGGTTACGGT AGGACCGTTA ACTTGTCAAA CTTCCAAACG

TGACCACTGA ATGTAGCCAG GACCTTTTGT TCTTTCTGTG TGCCATGTAT GCCCCCATTT     600
ACTGGTGACT TACATCGGTC CTGGAAAACA AGAAAGACAC ACGGTACATA CGGGGGTAAA

GTACCATCGA TTTCCAGCAT GAACCAATTA AGCCTTGCAA GTCCGTGTGC GAAAGGGCCA     660
CATGGTAGCT AAAGGTCGTA CTTGGTTAAT TCGGAACGTT CAGGCACACG CTTTCCCGGT

GGGCCGGCTG TGAGCCCATT CTCATAAAGT ACCGGCACAC TTGGCCAGAG AGCCTGGCAT     720
CCCGGCCGAC ACTCGGGTAA GAGTATTTCA TGGCCGTGTG AACCGGTCTC TCGGACCGTA

GTGAAGAGCT GCCCGTATAT GACAGAGGAG TCTGCATCTC CCCAGAGGCT ATCGTCACAG     780
CACTTCTCGA CGGGCATATA CTGTCTCCTC AGACGTAGAG GGGTCTCCGA TAGCAGTGTC

TGGAACAAGG AACAGATTCA ATGCCAGACT TCTCCATGGA TTCAAACAAT GGAAATTGCG     840
ACCTTGTTCC TTGTCTAAGT TACGGTCTGA AGAGGTACCT AAGTTTGTTA CCTTTAACGC

GAAGCGGCAG GCAGCACTGT AAATGCAAGC CCATGAAGGC AACCCAAAAG ACGTATCTCA     900
CTTCGCCGTC CGTCGTGACA TTTACGTTCG GGTACTTCCG TTGGGTTTTC TGCATAGAGT

AGAATAATTA CAATTATGTA ATCAGAGCAA AAGTGAAAGA GGTGAAAGTG AAATGCCACG     960
TCTTATTAAT GTTAATACAT TAGTCTCGTT TTCACTTTCT CCACTTTCAC TTTACGGTGC

ACGCAACAGC AATTGTGGAA GTAAAGGAGA TTCTCAAGTC TTCCCTAGTG AACATTCCTA    1020
TGCGTTGTCG TTAACACCTT CATTTCCTCT AAGAGTTCAG AAGGGATCAC TTGTAAGGAT
```

Figure 4A

SUBSTITUTE SHEET (RULE 26)

```
AAGACACAGT GACACTGTAC ACCAACTCAG GCTGCTTGTG CCCCCAGCTT GTTGCCAATG   1080
TTCTGTGTCA CTGTGACATG TGGTTGAGTC CGACGAACAC GGGGGTCGAA CAACGGTTAC

AGGAATACAT AATTATGGGC TATGAAGACA AAGAGCGTAC CAGGCTTCTA CTAGTGGAAG   1140
TCCTTATGTA TTAATACCCG ATACTTCTGT TTCTCGCATG GTCCGAAGAT GATCACCTTC

GATCCTTGGC CGAAAAATGG AGAGATCGTC TTGCTAAGAA AGTCAAGCGC TGGGATCAAA   1200
CTAGGAACCG GCTTTTTACC TCTCTAGCAG AACGATTCTT TCAGTTCGCG ACCCTAGTTT

AGCTTCGACG TCCCAGGAAA AGCAAAGACC CCGTGGCTCC AATTCCCAAC AAAAACAGCA   1260
TCGAAGCTGC AGGGTCCTTT TCGTTTCTGG GGCACCGAGG TTAAGGGTTG TTTTTGTCGT

ATTCCAGACA AGCGCGTAGT TAGACTAACG GAAAGGTGTA TGGAAACTCT ATGGACTTTG   1320
TAAGGTCTGT TCGCGCATCA ATCTGATTGC CTTTCCACAT ACCTTTGAGA TACCTGAAAC

AAACTAAGAT TTGCATTGTT GGAAGAGCAA AAAAGAAATT GCACTACAGC ACGTTATATT   1380
TTTGATTCTA AACGTAACAA CCTTCTCGTT TTTTCTTTAA CGTGATGTCG TGCAATATAA

CTATTGTTTA CTACAAGAAG CTGGTTTAGT TGATTGTAGT TCTCCTTTCC TTCTTTTTTT   1440
GATAACAAAT GATGTTCTTC GACCAAATCA ACTAACATCA AGAGGAAAGG AAGAAAAAAA

TTATAACTAT ATTTGCACGT GTTCCCAGGC AATTGTTTTA TTCAACTTCC AGTGACAGAG   1500
AATATTGATA TAAACGTGCA CAAGGGTCCG TTAACAAAAT AAGTTGAAGG TCACTGTCTC

CAGTGACTGA ATGTCTCAGC CTAAAGAAGC TCAATTCATT TCTGATCAAC TAATGGTGAC   1560
GTCACTGACT TACAGAGTCG GATTTCTTCG AGTTAAGTAA AGACTAGTTG ATTACCACTG

AAGTGTTTGA TACTTGGGGA AAGTGAACTA ATTGCAATGG TAAATCAGAG AAAAGTTGAC   1620
TTCACAAACT ATGAACCCCT TTCACTTGAT TAACGTTACC ATTTAGTCTC TTTTCAACTG

CAATGTTGCT TTTCCTGTAG ATGAACAAGT GAGAGATCAC ATTTAAATGA TGATCACTTT   1680
GTTACAACGA AAAGGACATC TACTTGTTCA CTCTCTAGTG TAAATTTACT ACTAGTGAAA

CCATTTAATA CTTTCAGCAG TTTTAGTTAG ATGACATGTA GGATGCACCT AAATCTAAAT   1740
GGTAAATTAT GAAAGTCGTC AAAATCAATC TACTGTACAT CCTACGTGGA TTTAGATTTA

ATTTTATCAT AAATGAAGAG CTGGTTTAGA CTGTATGGTC ACTGTTGGGA AGGTAAATGC   1800
TAAAATAGTA TTTACTTCTC GACCAAATCT GACATACCAG TGACAACCCT TCCATTTACG

CTACTTTGTC AATTCTGTTT TAAAAATTGC CTAAATAAAT ATTAAGTCCT AAATAAAAAA   1860
GATGAAACAG TTAAGACAAA ATTTTTAACG GATTTATTTA TAATTCAGGA TTTATTTTTT

AAAAAAAAAA AAAAA
TTTTTTTTTT TTTTT
```

Figure 4B

SUBSTITUTE SHEET (RULE 26)

```
MLLLFRAIPM LLLGLMVLQT DCEIAQYYID EEEPPGTVIA VLSQRSIPNT TDIPATNFRL    60
NEQPNNSLIG VRESDGQLSI MERIDREQIC EQSLRCHLAL DVVSPSKDHF KLLNVKVEVR   120
DINDHSPHFP SEIMHVEVSE SSSVGTRIPL EIAIDEDVGS NEIQNFQISN NRHFSIDVLT   180
RADGVKYADL VLMRELDREI QPTYIMELLA MDGGVPSLSG TAVVNIKVLD FNDNSPVFER   240
STIAVDLVED APLGYLLLEL HATDQDEGVN GEIVYGFSTL ASQEVRQLFK IESRTGSVTL   300
EGQVDFEYKQ TYEFEVQAQD LGPNPLTATC KVTVHILDVN DNTPAITITP LTTVNAGVAY   360
IPETATKEMF IALISTTDRA SGSNGQVRCT LYGHEHFKLQ QAYEDSYMIV TTSTLDRENI   420
AAYSLTVVAE DLGFPSLKTK KYTTVKVSDE MDNAPVFSKP QYEASILENN APGSYITTVI   480
ARDSDSDQNG KVHYRLVDAK VNGQSLTTFV SLDADSGVLR AVRSLDYEKL KQLDFEIEAA   540
DNGIPQLSTR VQLHLRIVDQ NDNCPVITNP LLNNGSGEVL LPISAPQNYL VFQLKAEDSD   600
EGHNSQLFYT ILRDPSRLFA IKKESGEVFL KKQLNSDESE DLSIVVAVYD LGRPSLSTHA   660
TVKFILTDSF PSNVEVVILQ PSAEEQHQID MSIIFIAVLA GGCALLLLAI FFVACTCKKK   720
AGEFKQVPEQ EGTCNEERLL STPSPQSVSS SLSQSESCQL SINTESENCS VSSNQEQHDQ   780
TGIKHSISVP SYHTSGMHLD NCAMSISGHS HMGHISTKVQ HAKEIVTSMT VTLILVENQK   840
RRALSSQCRH KPVLNTQMNQ QGSDMPITIS ATESTRVQKM GTAHCNMKRA IDCLTL
```

Figure 5

SUBSTITUTE SHEET (RULE 26)

```
GAATTCCCAG AGATGARCTC CTTGAGATTG TTTTAAATGA CTGCAGGTCT GGAAGCATTC     60
CTTAAGGGTC TCTACTTGAG GAACTCTAAC AAAATTTACT GACGTCCAGA CCTTCCTAAG

ACATTGCCAC ACTGTTTCTA GGCATGAAAA AACTGCAAGT TTCAACTTTG TTTTTGGTGC    120
TGTAACGGTG TGACAAAGAT CCGTACTTTT TTGACGTTCA AAGTTGAAAC AAAAACCACG

AACTTTGATT CTTCAAGATG CTGCTTCTCT TCAGAGCCAT TCCAATGCTG CTGTTGGGAC    180
TTGAAACTAA GAAGTTCTAC GACGAAGAGA AGTCTCGGTA AGGTTACGAC GACAACCCTG

TGATGGTTTT ACAAACAGAC TGTGAAATTG CCCAGTACTA CATAGATGAA GAAGAACCCC    240
ACTACCAAAA TGTTTGTCTG ACACTTTAAC GGGTCATGAT GTATCTACTT CTTCTTGGGG

CTGGCACTGT AATTGCAGTG TTGTCACAAC ACTCCATATT TAACACTACA GATATACCTG    300
GACCGTGACA TTAACGTCAC AACAGTGTTG TGAGGTATAA ATTGTGATGT CTATATGGAC

CAACCAATTT CCGTCTAATG AAGCAATTTA ATAATTCCCT TATCGGAGTC CGTGAGAGTG    360
GTTGGTTAAA GGCAGATTAC TTCGTTAAAT TATTAGGGA ATAGCCTCAG GCACTCTCAC

ATGGGCAGCT GAGCATCATG GAGAGGATTG ACCGGGAGCA AATCTGCAGG CAGTCCCTTC    420
TACCCGTCGA CTCGTAGTAC CTCTCCTAAC TGGCCCTCGT TTAGACGTCC GTCAGGGAAG

ACTGCAACCT GGCTTTGGAT GTGGTCAGCT TTTCCAAAGG ACACTTCAAG CTTCTGAACG    480
TGACGTTGGA CCGAAACCTA CACCAGTCGA AAAGGTTTCC TGTGAAGTTC GAAGACTTGC

TGAAAGTGGA GGTGAGAGAC ATTAATGACC ATAGCCCTCA CTTTCCCAGT GAAATAATGC    540
ACTTTCACCT CCACTCTCTG TAATTACTGG TATCGGGAGT GAAAGGGTCA CTTTATTACG

ATGTGGAGGT GTCTGAAAGT TCCTCTGTGG GCACCAGGAT TCCTTTAGAA ATTGCAATAG    600
TACACCTCCA CAGACTTTCA AGGAGACACC CGTGGTCCTA AGGAAATCTT TAACGTTATC

ATGAAGATGT TGGGTCCAAC TCCATCCAGA ACTTTCAGAT CTCAAATAAT AGCCACTTCA    660
TACTTCTACA ACCCAGGTTG AGGTAGGTCT TGAAAGTCTA GAGTTTATTA TCGGTGAAGT

GCATTGATGT GCTAACCAGA GCAGATGGGG TGAAATATGC AGATTTAGTC TTAATGAGAG    720
CGTAACTACA CGATTGGTCT CGTCTACCCC ACTTTATACG TCTAAATCAG AATTACTCTC

AACTGGACAG GGAAATCCAG CCAACATACA TAATGGAGCT ACTAGCAATG GATGGGGGTG    780
TTGACCTGTC CCTTTAGGTC GGTTGTATGT ATTACCTCGA TGATCGTTAC CTACCCCCAC

TACCATCACT ATCTGGTACT GCAGTGGTTA ACATCCGAGT CCTGGACTTT AATGATAACA    840
ATGGTAGTGA TAGACCATGA CGTCACCAAT TGTAGGCTCA GGACCTGAAA TTACTATTGT

GCCCAGTGTT TGAGAGAAGC ACCATTGCTG TGGACCTAGT AGAGGATGCT CCTCTGGGAT    900
CGGGTCACAA ACTCTCTTCG TGGTAACGAC ACCTGGATCA TCTCCTACGA GGAGACCCTA

ACCTTTTGTT GGAGTTACAT GCTACTGACG ATGATGAAGG AGTGAATGGA GAAATTGTTT    960
TGGAAAACAA CCTCAATGTA CGATGACTGC TACTACTTCC TCACTTACCT CTTTAACAAA

ATGGATTCAG CACTTTGGCA TCTCAAGAGG TACGTCAGCT ATTTAAAATT AACTCCAGAA   1020
TACCTAAGTC GTGAAACCGT AGAGTTCTCC ATGCAGTCGA TAAATTTTAA TTGAGGTCTT
```

Figure 6A

SUBSTITUTE SHEET (RULE 26)

```
CTGGCAGTGT TACTCTTGAA GGCCAAGTTG ATTTTGAGAC CAAGCAGACT TACGAATTTG  1080
GACCGTCACA ATGAGAACTT CCGGTTCAAC TAAAACTCTG GTTCGTCTGA ATGCTTAAAC

AGGTACAAGC CCAAGATTTG GGCCCCAACC CACTGACTGC TACTTGTAAA GTAACTGTTC  1140
TCCATGTTCG GGTTCTAAAC CCGGGGTTGG GTGACTGACG ATGAACATTT CATTGACAAG

ATATACTTGA TGTAAATGAT AATACCCCAG CCATCACTAT TACCCCTCTG ACTACTGTAA  1200
TATATGAACT ACATTTACTA TTATGGGGTC GGTAGTGATA ATGGGGAGAC TGATGACATT

ATGCAGGAGT TGCCTATATT CCAGAAACAG CCACAAAGGA GAACTTTATA GCTCTGATCA  1260
TACGTCCTCA ACGGATATAA GGTCTTTGTC GGTGTTTCCT CTTGAAATAT CGAGACTAGT

GCACTACTGA CAGAGCCTCT GGATCTAATG GACAAGTTCG CTGTACTCTT TATGGACATG  1320
CGTGATGACT GTCTCGGAGA CCTAGATTAC CTGTTCAAGC GACATGAGAA ATACCTGTAC

AGCACTTTAA ACTACAGCAA GCTTATGAGG ACAGTTACAT GATAGTTACC ACCTCTACTT  1380
TCGTGAAATT TGATGTCGTT CGAATACTCC TGTCAATGTA CTATCAATGG TGGAGATGAA

TAGACAGGGA AAACATAGCA GCGTACTCTT TGACAGTAGT TGCAGAAGAC CTTGGCTTCC  1440
ATCTGTCCCT TTTGTATCGT CGCATGAGAA ACTGTCATCA ACGTCTTCTG GAACCGAAGG

CCTCATTGAA GACCAAAAAG TACTACACAG TCAAGGTTAG TGATGAGAAT GACAATGCAC  1500
GGAGTAACTT CTGGTTTTTC ATGATGTGTC AGTTCCAATC ACTACTCTTA CTGTTACGTG

CTGTATTTTC TAAACCCCAG TATGAAGCTT CTATTCTGGA AAATAATGCT CCAGGCTCTT  1560
GACATAAAAG ATTTGGGGTC ATACTTCGAA GATAAGACCT TTTATTACGA GGTCCGAGAA

ATATAACTAC AGTGATAGCC AGAGACTCTG ATAGTGATCA AAATGGCAAA GTAAATTACA  1620
TATATTGATG TCACTATCGG TCTCTGAGAC TATCACTAGT TTTACCGTTT CATTTAATGT

GACTTGTGGA TGCAAAAGTG ATGGGCCAGT CACTAACAAC ATTTGTTCT CTTGATGCGG  1680
CTGAACACCT ACGTTTTCAC TACCCGGTCA GTGATTGTTG TAAACAAAGA GAACTACGCC

ACTCTGGAGT ATTGAGAGCT GTTAGGTCTT TAGACTATGA AAAACTTAAA CAACTGGATT  1740
TGAGACCTCA TAACTCTCGA CAATCCAGAA ATCTGATACT TTTTGAATTT GTTGACCTAA

TTGAAATTGA AGCTGCAGAC AATGGGATCC CTCAACTCTC CACTCGCGTT CAACTAAATC  1800
AACTTTAACT TCGACGTCTG TTACCCTAGG GAGTTGAGAG GTGAGCGCAA GTTGATTTAG

TCAGAATAGT TGATCAAAAT GATAATTGCC CTGTGATAAC TAATCCTCTT CTTAATAATG  1860
AGTCTTATCA ACTAGTTTTA CTATTAACGG GACACTATTG ATTAGGAGAA GAATTATTAC

GCTCGGGTGA AGTTCTGCTT CCCATCAGCG CTCCTCAAAA CTATTTAGTT TTCCAGCTCA  1920
CGAGCCCACT TCAAGACGAA GGGTAGTCGC GAGGAGTTTT GATAAATCAA AAGGTCGAGT

AAGCCGAGGA TTCAGATGAA GGGCACAACT CCCAGCTGTT CTATACCATA CTGAGAGATC  1980
TTCGGCTCCT AAGTCTACTT CCCGTGTTGA GGGTCGACAA GATATGGTAT GACTCTCTAG

CAAGCAGATT GTTTGCCATT AACAAAGAAA GTGGTGAAGT GTTCCTGAAA AAACAATTAA  2040
GTTCGTCTAA CAAACGGTAA TTGTTTCTTT CACCACTTCA CAAGGACTTT TTTGTTAATT

ACTCTGACCA TTCAGAGGAC TTGAGCATAG TAGTTGCAGT GTATGACTTG GGAAGACCTT  2100
TGAGACTGGT AAGTCTCCTG AACTCGTATC ATCAACGTCA CATACTGAAC CCTTCTGGAA

CATTATCCAC CAATGCTACA GTTAAATTCA TCCTCACCGA CTCTTTTCCT TCTAACGTTG  2160
GTAATAGGTG GTTACGATGT CAATTTAAGT AGGAGTGGCT GAGAAAAGGA AGATTGCAAC
```

Figure 6B

SUBSTITUTE SHEET (RULE 26)

```
AAGTCGTTAT TTTGCAACCA TCTGCAGAAG AGCAGCAGCA GATCGATATG TCCATTATAT   2220
TTCAGCAATA AAACGTTGGT AGACGTCTTC TCGTCGTGGT CTAGCTATAC AGGTAATATA

TCATTGCAGT GCTGGCTGGT GGTTGTGCTT TGCTACTTTT GGCCATCTTT TTTGTGGCCT   2280
AGTAACGTCA CGACCGACCA CCAACACGAA ACGATGAAAA CCGGTAGAAA AAACACCGGA

GTACTTGTAA AAAGAAAGCT GGTGAATTTA AGCAGGTACC TGAACAACAC GGAACATGCA   2340
CATGAACATT TTTCTTTCGA CCACTTAAAT TCGTCCATGG ACTTGTTGTG CCTTGTACGT

ATGAAGAACG CCTGTTAAGC ACCCCATCTC CCCAGTCGGT CTCTTCTTCT TTGTCTCAGT   2400
TACTTCTTGC GGACAATTCG TGGGGTAGAG GGGTCAGCCA GAGAAGAAGA AACAGAGTCA

CTGAGTCATG CCAACTCTCC ATCAATACTG AATCTGAGAA TTGCAGCGTG TCCTCTAACC   2460
GACTCAGTAC GGTTGAGAGG TAGTTATGAC TTAGACTCTT AACGTCGCAC AGGAGATTGG

AAGAGCAGCA TCAGCAAACA GGCATAAAGC ACTCCATCTC TGTACCATCT TATCACACAT   2520
TTCTCGTCGT AGTCGTTTGT CCGTATTTCG TGAGGTAGAG ACATGGTAGA ATAGTGTGTA

CTGGTTGGCA CCTGGACAAT TGTGCAATGA GCATAAGTGG ACATTCTCAC ATGGGGCACA   2580
GACCAACCGT GGACCTGTTA ACACGTTACT CGTATTCACC TGTAAGAGTG TACCCCGTGT

TTAGTACAAA GGTACAGTGG GCAAAGGAGA TAGTGACTTC AATGACAGTG ACTCTGATAC   2640
AATCATGTTT CCATGTCACC CGTTTCCTCT ATCACTGAAG TTACTGTCAC TGAGACTATG

TAGTGGAGAA TCAGAAAAGA AGAGCATTGA GCAGCCAATG CAGGCACAAG CCAGTGCTCA   2700
ATCACCTCTT AGTCTTTTCT TCTCGTAACT CGTCGGTTAC GTCCGTGTTC GGTCACGAGT

ATACACAGAT GAATCAGCAG GGTTCCGACA TGCCGATAAC TATTTCAGCC ACCGAATCAA   2760
TATGTGTCTA CTTAGTCGTC CCAAGGCTGT ACGGCTATTG ATAAAGTCGG TGGCTTAGTT

CAAGGGTCCA GAAAATGGGA ACTGCACATT GCAATATGAA AAGGGCTATA GACTGTCTTA   2820
GTTCCCAGGT CTTTTACCCT TGACGTGTAA CGTTATACTT TTCCCGATAT CTGACAGAAT

CTCTGTAGCT CCTGTATATT ACAATACCTA CCATGCAAGA ATGCCTAACC TGCACATACC   2880
GAGACATCGA GGACATATAA TGTTATGGAT GGTACGTTCT TACGGATTGG ACGTGTATGG

GAACCATACC CTTAGAGACC CTTATTACCA TATCAATAAT CCTGTTGCTA ATCGGATGCA   2940
CTTGGTATGG GAATCTCTGG GAATAATGGT ATAGTTATTA GGACAACGAT TAGCCTACGT

GGCCGAATAT GAAAGAGATT TAGTCAACAG AAGTGCAACG TTATCTCCGC AGAGATCGTC   3000
CGGCCTTATA CTTTCTCTAA ATCAGTTGTC TTCACGTTGC AATAGAGGCG TCTCTAGCAG

TAGCAGATAC CAAGAATTCA ATTACAGTCC GCAGATATCA AGACAGCTTC ATCCTTCAGA   3060
ATCGTCTATG GTTCTTAAGT TAATGTCAGG CGTCTATAGT TCTGTCGAAG TAGGAAGTCT

AATTGCTACA ACCTTTTAAT CATTAGGCAT GCAAGTGAGA ATGCACAAAG GCAAGTGCTT   3120
TTAACGATGT TGGAAAATTA GTAATCCGTA CGTTCACTCT TACGTGTTTC CGTTCACGAA

TAGCATGAAA GCTAAATATA TGGAGTCTCC CCTTTCCCTC TGATGGATGG GGGGAGACAC   3180
ATCGTACTTT CGATTTATAT ACCTCAGAGG GGAAAGGGAG ACTACCTACC CCCCTCTGTG

AGGACAGTGC ATAAATATAC AGCTGCTTTC TATTTGCATT TCACTTGGGA ATTTTTTGTT   3240
TCCTGTCACG TATTTATATG TCGACGAAAG ATAAACGTAA AGTGAACCCT TAAAAAACAA

TTTTTTACAT ATTTATTTTT CCTGAATTGA ATGTGACATT GTCCTGTCAC CTAACTAGCA   3300
AAAAAATGTA TAAATAAAAA GGACTTAACT TACACTGTAA CAGGACAGTG GATTGATCGT
```

Figure 6C

SUBSTITUTE SHEET (RULE 26)

```
ATTAAATCCA CAGACCTACA GTCAAATATT TGAGGCCCCC TGAAACAGCA CATCAGTCAG   3360
TAATTTAGGT GTCTGGATGT CAGTTTATAA ACTCCCGGGG ACTTTGTCGT GTAGTCAGTC

GACCTAAAGT GGCCTTTTTA CTTTTAGCAG CTCCTGGGTC TGCCCTCTGT GTGAATCAGC   3420
CTGGATTTCA CCGGAAAAAT GAAAATCGTC GAGGACCCAG ACGGGAGACA CAATTAGTCG

CCCTGGTCAA GTCCTGAGTA GGATCATGGC GTTTTTATAT GCATCTCACC TACTTTGGAC   3480
GGGACCAGTT CAGGACTCAT CCTAGTACCG CAAAAATATA CGTAGAGTGG ATGAAACCTG

GTGATTTACA CATAATAGGA AACGCTTGGT TTCAGTGAAG TCTGTGTTGT ATATATTCTG   3540
CACTAAATGT GTATTATCCT TTGCGAACCA AAGTCACTTC AGACACAACA TATATAAGAC

TTATATACAC GCATTTTGTG TTTGTGTATA TATTTCAAGT CCATTCAGAT ATGTGTATAT   3600
AATATATGTG CGTAAAACAC AAACACATAT ATAAAGTTCA GGTAAGTCTA TACACATATA

AGTGCAGACC TTGTAAATTA AATATTCTGA TACTTTTTCC TCAATAAATA TTTAAAT
TCACGTCTGG AACATTTAAT TTATAAGACT ATGAAAAAGG AGTTATTTAT AAATTTA
```

Figure 6D

MVCCGPGRML LGWAGLLVLA ALCLLQVPGA QAAACEPVRI PLCKSLPWSM TSMPNHLHHS 60

TQANAILAMR QFEGLLGTHC SPDLLPFLCA MYAPICTIDF QHEPIKPCKS VCERARQGCE 120

PILIKYRHSW PESLACDELP VYDRGVCISP EAIVTADGAD FPMDSSTGHC RGASSERCKC 180

KPVRATQKTY FRNNYNYVIR AKVKEVKMKC HDVTAVVEVK EILKASLVNI PRDTVNLYTT 240

SGCLCPPLTV NEEYVIMGYE DEKRSRLLLV EGSIAEKMKD RLGKKVKRMD MKLRHLGLGK 300

TDAEDSTQNQ KSGRNSNPRP ARS.

Figure 7

SUBSTITUTE SHEET (RULE 26)

```
AAGCCTGGGA CCATGGTCTG CTGCGGCCCG GGACGGATGC TGCTAGGATG GGCCGGGTTG      60
TTCGGACCCT GGTACCAGAC GACGCCGGGC CCTGCCTACG ACGATCCTAC CCGGCCCAAC

CTAGTCCTGG CTGCTCTCTG CCTGCTCCAG GTGCCCGGAG CTCAGGCTGC AGCCTGTGAG     120
GATCAGGACC GACGAGAGAC GGACGAGGTC CACGGGCCTC GAGTCCGACG TCGGACACTC

CCTGTCCGCA TCCCGCTGTG CAAGTCCCTT CCCTGGAACA TGACCAAGAT GCCCAACCAC     180
GGACAGGCGT AGGGCGACAC GTTCAGGGAA GGGACCTTGT ACTGGTTCTA CGGGTTGGTG

CTGCACCACA GCACCCAGGC TAACGCCATC CTGGCCATGG AACAGTTCGA AGGGCTGCTG     240
GACGTGGTGT CGTGGGTCCG ATTGCGGTAG GACCGGTACC TTGTCAAGCT TCCCGACGAC

GGCACCCACT GCAGCCCGGA TCTTCTCTTC TTCCTCTGTG CAATGTACGC ACCCATTTGC     300
CCGTGGGTGA CGTCGGGCCT AGAAGAGAAG AAGGAGACAC GTTACATGCG TGGGTAAACG

ACCATCGACT TCCAGCACGA GCCCATCAAG CCCTGCAAGT CTGTGTGTGA GCGCGCCCGA     360
TGGTAGCTGA AGGTCGTGCT CGGGTAGTTC GGGACGTTCA GACACACACT CGCGCGGGCT

CAGGGCTGCG AGCCCATTCT CATCAAGTAC CGCCACTCGT GGCCGGAAAG CTTGGCCTGC     420
GTCCCGACGC TCGGGTAAGA GTAGTTCATG GCGGTGAGCA CCGGCCTTTC GAACCGGACG

GACGAGCTGC CGGTGTACGA CCGCGGCGTG TGCATCTCTC CTGAGGCCAT CGTCACCGCG     480
CTGCTCGACG GCCACATGCT GGCGCCGCAC ACGTAGAGAG GACTCCGGTA GCAGTGGCGC

GACGGAGCGG ATTTTCCTAT GGATTCAAGT ACTGGACACT GCAGAGGGGC AAGCAGCGAA     540
CTGCCTCGCC TAAAAGGATA CCTAAGTTCA TGACCTGTGA CGTCTCCCCG TTCGTCGCTT

CGTTGCAAAT GTAAGCCTGT CAGAGCTACA CAGAAGACCT ATTTCCGGAA CAATTACAAC     600
GCAACGTTTA CATTCGGACA GTCTCGATGT GTCTTCTGGA TAAAGGCCTT GTTAATGTTG

TATGTCATCC GGGCTAAAGT TAAAGAGGTA AAGATGAAAT GTCATGATGT GACCGCCGTT     660
ATACAGTAGG CCCGATTTCA ATTTCTCCAT TTCTACTTTA CAGTACTACA CTGGCGGCAA

GTGGAAGTGA AGGAAATTCT AAAGGCATCA CTGGTAAACA TTCCAAGGGA CACCGTCAAT     720
CACCTTCACT TCCTTTAAGA TTTCCGTAGT GACCATTTGT AAGGTTCCCT GTGGCAGTTA

CTTTATACCA CCTCTGGCTG CCTCTGTCCT CCACTTACTG TCAATGAGGA ATATGTCATC     780
GAAATATGGT GGAGACCGAC GGAGACAGGA GGTGAATGAC AGTTACTCCT TATACAGTAG

ATGGGCTATG AAGACGAGGA ACGTTCCAGG TTACTCTTGG TAGAAGGCTC TATAGCTGAG     840
TACCCGATAC TTCTGCTCCT TGCAAGGTCC AATGAGAACC ATCTTCCGAG ATATCGACTC

AAGTGGAAGG ATCGGCTTGG TAAGAAAGTC AAGCGCTGGG ATATGAAACT CCGACACCTT     900
TTCACCTTCC TAGCCGAACC ATTCTTTCAG TTCGCGACCC TATACTTTGA GGCTGTGGAA

GGACTGGGTA AAACTGATGC TAGCGATTCC ACTCAGAATC AGAAGTCTGG CAGGAACTCT     960
CCTGACCCAT TTTGACTACG ATCGCTAAGG TGAGTCTTAG TCTTCAGACC GTCCTTGAGA
```

Figure 8A

SUBSTITUTE SHEET (RULE 26)

```
AATCCCCGGC CAGCACGCAG CTAAATCCTG AAATGTAAAA GGCCACACCC ACGGACTCCC   1020
TTAGGGGCCG GTCGTGCGTC GATTTAGGAC TTTACATTTT CCGGTGTGGG TGCCTGAGGG

TTCTAAGACT GGCGCTGGTG GACTAACAAA GGAAAACCGC ACAGTTGTGC TCGTGACCGA   1080
AAGATTCTGA CCGCGACCAC CTGATTGTTT CCTTTTGGCG TGTCAACACG AGCACTGGCT

TTGTTTACCG CAGACACCGC GTGGCTACCG AAGTTACTTC CGGTCCCCTT TCTCCTGCTT   1140
AACAAATGGC GTCTGTGGCG CACCGATGGC TTCAATGAAG GCCAGGGGAA AGAGGACGAA

CTTAATGGCG TGGGGTTAGA TCCTTTAATA TGTTATATAT TCTGTTTCAT CAATCACGTG   1200
GAATTACCGC ACCCCAATCT AGGAAATTAT ACAATATATA AGACAAAGTA GTTAGTGCAC

GGGACTGTTC TTTTGCAACC AGAATAGTAA ATTAAATATG TTGATGCTAA GGTTTCTGTA   1260
CCCTGACAAG AAAACGTTGG TCTTATCATT TAATTTATAC AACTACGATT CCAAAGACAT

CTGGACTCCC TGGGTTTAAT TTGGTGTTCT GTACCCTGAT TGAGAATGCA ATGTTTCATG   1320
GACCTGAGGG ACCCAAATTA AACCACAAGA CATGGGACTA ACTCTTACGT TACAAAGTAC

TAAAGAGAGA ATCCTGGTCA TATCTCAAGA ACTAGATATT GCTGTAAGAC AGCCTCTGCT   1380
ATTTCTCTCT TAGGACCAGT ATAGAGTTCT TGATCTATAA CGACATTCTG TCGGAGACGA

GCTGCGCTTA TAGTCTTGTG TTTGTATGCC TTTGTCCATT TCCCTCATGC TGTGAAAGTT   1440
CGACGCGAAT ATCAGAACAC AAACATACGG AAACAGGTAA AGGGAGTACG ACACTTTCAA

ATACATGTTT ATAAAGGTAG AACGGCATTT TGAAATCAGA CACTGCACAA GCAGAGTAGC   1500
TATGTACAAA TATTTCCATC TTGCCGTAAA ACTTTAGTCT GTGACGTGTT CGTCTCATCG

CCAACACCAG GAAGCATTTA TGAGGAAACG CCACACAGCA TGACTTATTT TCAAGATTGG   1560
GGTTGTGGTC CTTCGTAAAT ACTCCTTTGC GGTGTGTCGT ACTGAATAAA AGTTCTAACC

CAGGCAGCAA AATAAATAGT GTTGGGAGCC AAGAAAAGAA TATTTTGCCT GGTTAAGGGG   1620
GTCCGTCGTT TTATTTATCA CAACCCTCGG TTCTTTTCTT ATAAAACGGA CCAATTCCCC

CACACTGGAA TCAGTAGCCC TTGAGCCATT AACAGCAGTG TTCTTCTGGC AAGTTTTTGA   1680
GTGTGACCTT AGTCATCGGG AACTCGGTAA TTGTCGTCAC AAGAAGACCG TTCAAAAACT

TTTGTTCATA AATGTATTCA CGAGCATTAG AGATGAACTT ATAACTAGAC ATCTGTTGTT   1740
AAACAAGTAT TTACATAAGT GCTCGTAATC TCTACTTGAA TATTGATCTG TAGACAACAA

ATCTCTATAG CTCTGCTTCC TTCTAAATCA AACCCATTGT TGGATGCTCC CTCTCCATTC   1800
TAGAGATATC GAGACGAAGG AAGATTTAGT TTGGGTAACA ACCTACGAGG GAGAGGTAAG
```

Figure 8B

SUBSTITUTE SHEET (RULE 26)

ATAAATAAAT TTGGCTTGCT GTATTGGCCA GGAAAAGAAA GTATTAAAGT ATGCATGCAT 1860
TATTTATTTA AACCGAACGA CATAACCGGT CCTTTTCTTT CATAATTTCA TACGTACGTA

GTGCACCAGG GTGTTATTTA ACAGAGGTAT GTAACTCTAT AAAAGACTAT AATTTACAGG 1920
CACGTGGTCC CACAATAAAT TGTCTCCATA CATTGAGATA TTTTCTGATA TTAAATGTCC

ACACGGAAAT GTGCACATTT GTTTACTTTT TTTCTTCCTT TTGCTTTGGG CTTGTGATTT 1980
TGTGCCTTTA CACGTGTAAA CAAATGAAAA AAAGAAGGAA AACGAAACCC GAACACTAAA

TGGTTTTTGG TGTGTTTATG TCTGTATTTT GGGGGGTGGG TAGGTTTAAG CCATTGCACA 2040
ACCAAAAACC ACACAAATAC AGACATAAAA CCCCCCACCC ATCCAAATTC GGTAACGTGT

TTCAAGTTGA ACTAGATTAG AGTAGACTAG GCTCATTGGC CTAGACATTA TGATTTGAAT 2100
AAGTTCAACT TGATCTAATC TCATCTGATC CGAGTAACCG GATCTGTAAT ACTAAACTTA

TTGTGTTGTT TAATGCTCCA TCAAGATGTC TAATAAAAGG AATATGGTTG TCAACAGAGA 2160
AACACAACAA ATTACGAGGT AGTTCTACAG ATTATTTTCC TTATACCAAC AGTTGTCTCT

CGACAACAAC AACAAA
GCTGTTGTTG TTGTTT

Figure 8C

MVCGSPGGML LLRAGLLALA ALCLLRVPGA RAAACEPVRI PLCKELPWEM TKMPNHLHHS 60

TQANAILAIE QFEGLLGTHC SPDLLPFLCA MYAPICTIDF QHEPIKPCKS VCERARQGCE 120

PILIKYRHSW PENLACEELP VYDRGVCISP EAIVTADGAD FPMDSSNGNC RGASSERCKC 180

KPIRATQKTY FRNNYNYVIR AKVKEIKTKC HDVTAVVEVK EILKSSLVNI PRDTVNLYTS 240

SGCLCPPLNV NEEYIIMGYE DEERSRLLLV EGSIAEKWKD RLGKKVKRMD MKLRHLGLSK 300

SDSSNSDSTQ SQKSGRHSNP RQARN.

Figure 9

```
GGCGGAGCGG GCCTTTTGGC GTCCACTGCG CGGCTGCACC CTGCCCCATC TGCCGGGATC      60
CCGCCTCGCC CGGAAAACCG CAGGTGACGC GCCGACGTGG GACGGGGTAG ACGGCCCTAG

ATGGTCTGCG GCAGCCCGGG AGGGATGCTG CTGCTGCGGG CCGGGCTGCT TGCCCTGGCT     120
TACCAGACGC CGTCGGGCCC TCCCTACGAC GACGACGCCC GGCCCGACGA ACGGGACCGA

GCTCTCTGCC TGCTCCGGGT GCCCGGGGCT CGGGCTGCAG CCTGTGAGCC CGTCCGCATC     180
CGAGAGACGG ACGAGGCCCA CGGCCCCCGA GCCCGACGTC GGACACTCGG GCAGGCGTAG

CCCCTGTGCA AGTCCCTGCC CTGGAACATG ACTAAGATGC CCAACCACCT GCACCACAGC     240
GGGGACACGT TCAGGGACGG GACCTTGTAC TGATTCTACG GGTTGGTGGA CGTGGTGTCG

ACTCAGGCCA ACGCCATCCT GGCCATCGAG CAGTTCGAAG GTCTGCTGGG CACCCACTGC     300
TGAGTCCGGT TGCGGTAGGA CCGGTAGCTC GTCAAGCTTC CAGACGACCC GTGGGTGACG

AGCCCCGATC TGCTCTTCTT CCTCTGTGCC ATGTACGCGC CCATCTGCAC CATTGACTTC     360
TCGGGGCTAG ACGAGAAGAA GGAGACACGG TACATGCGCG GGTAGACGTG GTAACTGAAG

CAGCACGAGC CCATCAAGCC CTGTAAGTCT GTGTGCGAGC GGGCCCGGCA GGGCTGTGAG     420
GTCGTGCTCG GGTAGTTCGG GACATTCAGA CACACGCTCG CCCGGGCCGT CCCGACACTC

CCCATACTCA TCAAGTACCG CCACTCGTGG CCGGAGAACC TGGCCTGCGA GGAGCTGCCA     480
GGGTATGAGT AGTTCATGGC GGTGAGCACC GGCCTCTTGG ACCGGACGCT CCTCGACGGT

GTGTACGACA GGGGCGTGTG CATCTCTCCC GAGGCCATCG TTACTGCGGA CGGAGCTGAT     540
CACATGCTGT CCCCGCACAC GTAGAGAGGG CTCCGGTAGC AATGACGCCT GCCTCGACTA

TTTCCTATGG ATTCTAGTAA CGGAAACTGT AGAGGGGCAA GCAGTGAACG CTGTAAATGT     600
AAAGGATACC TAAGATCATT GCCTTTGACA TCTCCCCGTT CGTCACTTGC GACATTTACA

AAGCCTATTA GAGCTACACA GAAGACCTAT TTCCGGAACA ATTACAACTA TGTCATTCGG     660
TTCGGATAAT CTCGATGTGT CTTCTGGATA AAGGCCTTGT TAATGTTGAT ACAGTAAGCC

GCTAAAGTTA AAGAGATAAA GACTAAGTGC CATGATGTGA CTGCAGTAGT GGAGGTGAAG     720
CGATTTCAAT TTCTCTATTT CTGATTCACG GTACTACACT GACGTCATCA CCTCCACTTC

GAGATTCTAA AGTCCTCTCT GGTAAACATT CCACGGGACA CTGTCAACCT CTATACCAGC     780
CTCTAAGATT TCAGGAGAGA CCATTTGTAA GGTGCCCTGT GACAGTTGGA GATATGGTCG

TCTGGCTGCC TCTGCCCTCC ACTTAATGTT AATGAGGAAT ATATCATCAT GGGCTATGAA     840
AGACCGACGG AGACGGGAGG TGAATTACAA TTACTCCTTA TATAGTAGTA CCCGATACTT
```

Figure 10A

SUBSTITUTE SHEET (RULE 26)

```
GATGAGGAAC GTTCCAGATT ACTCTTGGTG GAAGGCTCTA TAGCTGAGAA GTGGAAGGAT    900
CTACTCCTTG CAAGGTCTAA TGAGAACCAC CTTCCGAGAT ATCGACTCTT CACCTTCCTA

CGACTCGGTA AAAAAGTTAA GCGCTGGGAT ATGAAGCTTC GTCATCTTGG ACTCAGTAAA    960
GCTGAGCCAT TTTTTCAATT CGCGACCCTA TACTTCGAAG CAGTAGAACC TGAGTCATTT

AGTGATTCTA GCAATAGTGA TTCCACTCAG AGTCAGAAGT CTGGCAGGAA CTCGAACCCC   1020
TCACTAAGAT CGTTATCACT AAGGTGAGTC TCAGTCTTCA GACCGTCCTT GAGCTTGGGG

CGGCAAGCAC GCAACTAAAT CCCGAAATAC AAAAAGTAAC ACAGTGGACT TCCTATTAAG   1080
GCCGTTCGTG CGTTGATTTA GGGCTTTATG TTTTTCATTG TGTCACCTGA AGGATAATTC

ACTTACTTGC ATTGCTGGAC TAGCAAAGGA AAATTGCACT ATTGCACATC ATATTCTATT   1140
TGAATGAACG TAACGACCTG ATCGTTTCCT TTTAACGTGA TAACGTGTAG TATAAGATAA

GTTTACTATA AAAATCATGT GATAACTGAT TATTACTTCT GTTTCTCTTT TGGTTTCTGC   1200
CAAATGATAT TTTTAGTACA CTATTGACTA ATAATGAAGA CAAAGAGAAA ACCAAAGACG

TTCTCTCTTC TCTCAACCCC TTTGTAATGG TTTGGGGGCA GACTCTTAAG TATATTGTGA   1260
AAGAGAGAAG AGAGTTGGGG AAACATTACC AAACCCCCGT CTGAGAATTC ATATAACACT

GTTTTCTATT TCACTAATCA TGAGAAAAAC TGTTCTTTTG CAATAATAAT AAATTAAACA   1320
CAAAAGATAA AGTGATTAGT ACTCTTTTTG ACAAGAAAAC GTTATTATTA TTTAATTTGT

TGCTGTTACC AGAGCCTCTT TGCTGAGTCT CCAGATGTTA ATTTACTTTC TGCACCCCAA   1380
ACGACAATGG TCTCGGAGAA ACGACTCAGA GGTCTACAAT TAAATGAAAG ACGTGGGGTT

TTGGGAATGC AATATTGGAT GAAAAGAGAG GTTTCTGGTA TTCACAGAAA GCTAGATATG   1440
AACCCTTACG TTATAACCTA CTTTTCTCTC CAAAGACCAT AAGTGTCTTT CGATCTATAC

CCTTAAAACA TACTCTGCCG ATCTAATTAC AGCCTTATTT TTGTATGCCT TTTGGGCATT   1500
GGAATTTTGT ATGAGACGGC TAGATTAATG TCGGAATAAA AACATACGGA AAACCCGTAA

CTCCTCATGC TTAGAAAGTT CCAAATGTTT ATAAAGGTAA AATGGCAGTT TGAAGTCAAA   1560
GAGGAGTACG AATCTTTCAA GGTTTACAAA TATTTCCATT TTACCGTCAA ACTTCAGTTT

TGTCACATAG GCAAAGCAAT CAAGCACCAG GAAGTGTTTA TGAGGAAACA ACACCCAAGA   1620
ACAGTGTATC CGTTTCGTTA GTTCGTGGTC CTTCACAAAT ACTCCTTTGT TGTGGGTTCT

TGAATTATTT TTGAGACTGT CAGGAAGTAA AATAAATAGG AGCTTAAGAA AGAACATTTT   1680
ACTTAATAAA AACTCTGACA GTCCTTCATT TTATTTATCC TCGAATTCTT TCTTGTAAAA

GCCTGATTGA GAAGCACAAC TGAAACCAGT AGCCGCTGGG GTGTTAATGG TAGCATTCTT   1740
CGGACTAACT CTTCGTGTTG ACTTTGGTCA TCGGCGACCC CACAATTACC ATCGTAAGAA

CTTTTGGCAA TACATTTGAT TTGTTCATGA ATATATTAAT CAGCATTAGA GAAATGAATT   1800
GAAAACCGTT ATGTAAACTA AACAAGTACT TATATAATTA GTCGTAATCT CTTTACTTAA

ATAACTAGAC ATCTGCTGTT ATCACCATAG TTTTGTTTAA TTTGCTTCCT TTTAAATAAA   1860
TATTGATCTG TAGACGACAA TAGTGGTATC AAAACAAATT AAACGAAGGA AAATTTATTT

CCCATTGGTG AAAGTCAAAA AAAAAAAAAA AAA
GGGTAACCAC TTTCAGTTTT TTTTTTTTTT TTT
```

Figure 10B

SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/10942

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :Please See Extra Sheet.
US CL : 530/300, 350; 514/2; 536/23.1
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/300, 350; 514/2; 536/23.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

DIALOG (MEDLINE, BIOSIS, EMBASE, WPI, USPATFULL) AUTHOR AND WORD. search terms: e.g. cerberus, xenopus

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y, P	BOUWMEESTER et al. Cerberus is a head-inducing secreted factor expressed in the anterior endoderm of Spemann's organizer. Nature. 15 August 1996, Vol. 382, No. 6592, pages 595-601, see entire document.	1-15

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
29 AUGUST 1997	11 SEP 1997

Name and mailing address of the ISA/US	Authorized officer
Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	HEATHER BAKALYAR
Facsimile No. (703) 305-3230	Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/10942

A. CLASSIFICATION OF SUBJECT MATTER:
IPC (6):

A01N 37/18; A61K 38/00; C07K 1/00, 2/00, 4/00, 7/00, 14/00, 16/00, 17/00; C07H 21/02, 21/04